3,4-difluorobenzenaldehyde oxime

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-difluorobenzenaldehyde oxime
• 英文别名: 1-(3,4-Difluorophenyl)-N-Hydroxymethanimine；(NE)-N-[(3,4-difluorophenyl)methylidene]hydroxylamine
• 化学式: C₇H₅F₂NO
• 分子量: 157.12
• InChiKey: KOAXKKBMLIYRCC-ONNFQVAWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-difluorobenzenaldehyde oxime 在 sodium azide 、 copper(II) ferrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以72%的产率得到5-(3,4-difluorophenyl)-1H-tetrazole
  参考文献：
  名称：

  CuFe2O4Nanoparticle Mediated Method for the Synthesis of 5-Substituted 1H-Tetrazoles from (E)-Aldoximes

  摘要：

  使用铜铁氧体纳米颗粒作为可重复使用的催化剂，采用了一种从各种（E）-醛肟和叠氮化钠合成5-取代的1H-四氮唑的策略。

  DOI：

  10.2174/1570178611666140210213157
• 作为产物：
  描述：

  3,4-二氟苯甲醛 在 盐酸羟胺 、 三乙胺 作用下， 以 乙醇 为溶剂， 生成 3,4-difluorobenzaldoxime 、 3,4-difluorobenzenaldehyde oxime
  参考文献：
  名称：

  (E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors

  摘要：

  A series of (E)-phenyl- and -heteroaryl- substituted O-benzoyl-(or acyl)oximes 3a-n were synthesized for evaluating their human lipoprotein-associated phospholiphase A(2) (Lp-PLA(2)) inhibitory activities. The less lipophilic derivatives 3a-c showed the most potent in vitro inhibitory activity on human Lp-PLA2. (c) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.063

文献信息

• ISOXAZOLE-PYRIDINE DERIVATIVES
  申请人：Buettelmann Bernd

  公开号：US20090143371A1

  公开（公告）日：2009-06-04

  The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R 1 to R 6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

  本发明涉及式I的异恶唑-吡啶衍生物 其中X，R1至R6如本文所述。这些化合物对GABA A α5受体结合位点具有活性，并可用于治疗认知障碍，如阿尔茨海默病。
• Aryl-isoxazol-4-yl-imidazole derivatives
  申请人：Buettelmann Bernd

  公开号：US20070161654A1

  公开（公告）日：2007-07-12

  The present invention is concerned with aryl-isoxazol-4-yl-imidazole derivatives of formula I: wherein R 1 to R 6 are as defmed in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.

  本发明涉及式I的芳基异噁唑-4-基咪唑衍生物：其中R1至R6如规范中定义，并且其药用酸盐。这类化合物具有高亲和力和选择性结合到GABA A α5受体结合位点，可能有助于作为认知增强剂或治疗认知障碍如阿尔茨海默病。
• Aminoacetamide acyl guanidines as beta-secretase inhibitors
  申请人：Gerritz Samuel

  公开号：US20060287287A1

  公开（公告）日：2006-12-21

  There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 2 , R 3 , R 4 , R 5 , R 25 , R 26 and R 27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列的取代酰基胍类化合物，符合以下化学式（Ik）或其立体异构体；或其药学上可接受的盐，其中R2、R3、R4、R5、R25、R26和R27如本文所定义，它们的药物组合物和使用方法。这些化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地说，抑制Aβ肽的产生。本公开涉及对β-淀粉样蛋白产生相关的神经疾病的治疗有用的化合物，如阿尔茨海默氏病和其他受抗淀粉样活性影响的病症。
• 6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance
  申请人：Ma Zhenkun

  公开号：US20060166906A1

  公开（公告）日：2006-07-27

  Compounds having formula (I) are useful for treating bacterial infections while avoiding the concomitant liability of gastrointestinal intolerance. Compositions containing the compounds and methods of treatment using the compounds are also disclosed.

  具有化学式（I）的化合物可用于治疗细菌感染，同时避免胃肠不耐受的风险。含有这些化合物的组合物以及使用这些化合物进行治疗的方法也被揭示。
• (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
  申请人：——

  公开号：US20030195226A1

  公开（公告）日：2003-10-16

  The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.

  本发明涉及新型肟羰基衍生物和包含该衍生物的药物组合物，其抑制脂肪酸酰胺水解酶。这些药物组合物对于治疗可以通过抑制脂肪酸酰胺水解酶而受到影响的疾病是有用的，包括但不限于神经病痛、呕吐、焦虑、改变进食行为、运动障碍、青光眼、脑损伤和心血管疾病。